Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Phase Ib/II trial of combination PD-1 therapy against kidney cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 773

Dr Chung-Han Lee - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Lee speaks with ecancer at ESMO 2017 about the early results of combining lenvatinib, one of the current treatment options against metastatic renal carcinoma, with anti-PD1 pembrolizumab.

He outlines the endpoints for the trial including overall response (OR) at 24 weeks, and notes the improved response for treatment naïve patients compared to those who had been previously treated.

While median PFS has not yet been met, Dr Lee is optimistic that the responses so far will translate to survival, and introduces phase III trials including lenvatinib and pembrolizumab as an investigative arm.

Fore more on this study, read our news coverage here.

Related videos

follow us

War on Cancer 2018

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation